Paris (France) and Cambridge (Massachusetts, U.S.), June 2, 2026, at 7:00 a.m. CET – Biophytis SA (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a pioneer in the development of transformative therapies targeting longevity, today announced the submission of the registration filing for its joint venture in Hong Kong with its Asian partners, including Ronghui Renhe Life Technology, a leading Chinese conglomerate primarily engaged in the manufacturing and distribution of healthcare products.
Biophytis announces completion of €5.3 million capital increase to fund its phase 2 trial in obesity
Biophytis today announces the completion of a capital increase through the issue of new shares, accompanied by share subscription warrants, with the removal of the preferential subscription rights of the…
